Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C2 | P52895 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5093148 | 1.00 | AKR1C2 (0.45) | AKR1C2FNTAFNTBMAPTCYP1A2 | |
| SCHEMBL5091286 | 0.84 | MAPT (0.42) | AKR1C2MAPTCYP1A2CYP2C19KDM4E | |
| SCHEMBL5098904 | 0.84 | MAPT (0.42) | AKR1C2MAPTCYP1A2CYP2C19KDM4E | |
| SCHEMBL5091295 | 0.84 | MAPT (0.42) | AKR1C2MAPTCYP1A2CYP2C19KDM4E | |
| SCHEMBL5099038 | 0.83 | MAPT (0.44) | MAPTCYP1A2CYP2C19KDM4EMEN1 | |
| SCHEMBL5099031 | 0.83 | MAPT (0.44) | MAPTCYP1A2CYP2C19KDM4EMEN1 | |
| SCHEMBL5091333 | 0.83 | MEN1 (0.41) | MAPTCYP1A2CYP2C19KDM4EMEN1 | |
| SCHEMBL5091344 | 0.83 | MEN1 (0.41) | MAPTCYP1A2CYP2C19KDM4EMEN1 | |
| SCHEMBL5094335 | 0.83 | MEN1 (0.41) | MAPTCYP1A2CYP2C19KDM4EMEN1 | |
| SCHEMBL5094382 | 0.83 | MAPT (0.44) | MAPTCYP1A2CYP2C19KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456208-B2 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-11-25 | — | — | US | claimed |
| US-20070249698-A1 | CCK-1 Receptor Modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | US | claimed |
| US-7250434-B2 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-31 | — | — | US | claimed |
| US-20050197377-A1 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-09-08 | — | — | US | claimed |
| US-7456208-B2 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-11-25 | — | — | US | disclosed |
| US-7456208-B2 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-11-25 | — | — | US | disclosed |
| US-7456208-B2 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-11-25 | — | — | US | disclosed |
| US-20070249698-A1 | CCK-1 Receptor Modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249698-A1 | CCK-1 Receptor Modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249698-A1 | CCK-1 Receptor Modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-7250434-B2 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-31 | — | — | US | disclosed |
| US-7250434-B2 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-31 | — | — | US | disclosed |
| US-7250434-B2 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-31 | — | — | US | disclosed |
| US-20050197377-A1 | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-09-08 | — | — | US | disclosed |
| WO-2005063716-A1 | IMIDAZOLES AND THEIR USE CCK-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197377-A1 | CCK-1 receptor modulators | CCKAR, CCKBR, GIPR | AKR1C2 3152/4885FNTA 4048/4885FNTB 3921/4885 |
| US-20070249698-A1 | CCK-1 Receptor Modulators | CCKAR, CCKBR, GIPR | AKR1C2 3152/4885FNTA 4048/4885FNTB 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.